Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Bristol Myers Squibb (NYSE:BMY) Stock Rises 4.7% With Phase 3 Data, Upgrades and a 4% Dividend Yield in View

Bristol Myers Squibb (NYSE:BMY) shares traded up 4.66% to $61.57 as a healthcare rotation lifted pharma stocks to record sector highs. Investors favored defensives amid volatility in artificial intelligence stocks and oil-driven macro jitters.

Nitish Kishor | 20 October 2026

Clene (NASDAQ:CLNN) Penny Stock Jumps 19% After Filing an ALS Drug Application With the FDA

Clene (NASDAQ:CLNN) shares traded up 18.84% to $3.91 after the company said it had submitted a New Drug Application to the U.S. Food and Drug Administration. The filing, made earlier in October, seeks accelerated approval of CNM-Au8 for the treatment of amyotrophic lateral sclerosis, …

Nitish Kishor | 20 October 2026

Why Is DaVita (NYSE:DVA) Stock Falling 5.7% When Healthcare Is Hitting Record Highs?

DaVita (NYSE:DVA) shares traded down 5.65% to $176.43 as the broader sector hit a record high. The healthcare sector was up roughly 1.8%, and Oppenheimer upgraded healthcare equipment and services to overweight. Volume was well above average.

Nitish Kishor | 20 October 2026

Elevance Health (NYSE:ELV) Stock Rises Into Wednesday's Q3 Report With a $4.66 EPS Estimate in Focus

Elevance Health (NYSE:ELV) shares traded up 2.02% to $438.94 as investors positioned for its Q3 report due Wednesday. Oppenheimer upgraded health care equipment and services to overweight and named Elevance a buy-rated pick, adding to a defensive rotation that has taken the sector near …

Nitish Kishor | 20 October 2026

Why Is Freenome (NASDAQ:FRNM) Stock Up 11% After Launching a Lung Cancer Blood Test?

Freenome (NASDAQ:FRNM) shares traded up 10.61% to $13.90 after the company launched SimpleScreen Lung, a laboratory-developed blood test for adults ages 50 to 80 with a smoking history of at least 20 pack-years who are not currently in guideline-recommended screening.

Nitish Kishor | 20 October 2026

Eli Lilly (NYSE:LLY) Stock: Foundayo Nod and Price Target Hikes Lift Shares 4% Toward All-Time Highs

Eli Lilly (NYSE:LLY) shares traded up 4.26% to $1,293.20 as investors digested a positive opinion from a European Medicines Agency committee on Foundayo, the company's oral obesity pill. Goldman Sachs raised its price target to $1,413 from $1,371, and BofA lifted its target to …

Nitish Kishor | 20 October 2026

Hims & Hers Health (NYSE:HIMS) Stock Gains 5.5% as a Germany Launch Extends Its International Push

Hims & Hers (NYSE:HIMS) shares traded up 5.54% to $29.71 after the telehealth company announced its launch in Germany, including its weight management offering and deeper investment in men's health. The launch builds on its international expansion after the June Eucalyptus deal.

Nitish Kishor | 20 October 2026

Why Is Johnson & Johnson (NYSE:JNJ) Stock Rising? A Faster Shockwave Catheter and Defensive Buying Both Help

Johnson & Johnson (NYSE:JNJ) shares traded up 2.08% to $259.06 after the company announced the U.S. launch of its Shockwave C2 Aero Fly Coronary IVL Catheter. The device delivers pulses at 2 Hz, cutting treatment time to 115 seconds from 230 seconds with earlier …

Nitish Kishor | 20 October 2026

Merck (NYSE:MRK) Stock Rises Ahead of Its Oct. 26 ESMO Investor Event and First Phase 3 Melanoma Vaccine Data

Merck (NYSE:MRK) shares traded up 2.99% to $147.93 as a broad healthcare rally lifted the sector to record highs. Investors rotated toward defensives as oil eased and technology names sold off last week. The move follows a 1.6% pullback on Monday.

Nitish Kishor | 20 October 2026

Why Is Moderna (NASDAQ:MRNA) Stock Up 6% Before Its Melanoma Vaccine Phase 3 Readout?

Moderna (NASDAQ:MRNA) shares traded up 5.78% to $240.00 as investors positioned for full Phase 3 data on intismeran, its personalized cancer vaccine co-developed with Merck (NYSE:MRK). The INTerpath-001 melanoma readout is due at ESMO.

Nitish Kishor | 20 October 2026
Support

Hi! How can we help you today?

Loading…